Skip to content
AnalystLens

Insmed 8-K Report, Regulation FD Disclosure (Jan 10, 2025)

Reports
Regulation FD·Exhibits & Filings
Filing Date
Filed January 10, 2025
Period End
January 10, 2025
Security
INSM
In the record · 2016–202610-K1110-Q338-K134

INSM filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 134 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’18Jan ’18
  2. Leadership change8-K · May ’20May ’20
  3. Material agreement8-K · Oct ’22Oct ’22
  4. Leadership change8-K · Oct ’26Oct ’26

01—Abstract

Summary

Summary of the 8-K filed January 10, 2025. Cited figures are marked; the original filing is the authoritative source.

Insmed Incorporated (Nasdaq: INSM) filed this Form 8-K under Item 7.01 (Regulation FD Disclosure) to furnish materials for a presentation by Chair and CEO Will Lewis at the 43rd Annual J.P.

Morgan Healthcare Conference on January 13, 2025. The company issued a press release on January 10, 2025 (Exhibit 99.1) and attached a slide presentation (Exhibit 99.2). The company reports preliminary, unaudited full-year 2024 global ARIKAYCE net product sales of approximately $363.7 milliona, up 19% year over year, with the United States at $254.8 million (up 14%), Japan at $87.7 million (up 33%), and Europe at $21.2 million (up 39%).

It guides 2025 global ARIKAYCE revenues to between $405 millionb and $425 million, which it describes as 11% to 17% growth over 2024. Final fourth-quarter and full-year 2024 results are to be reported in late February 2025. The filing's main pipeline update concerns brensocatib.

The company submitted a New Drug Application for brensocatib in bronchiectasis to the FDA in December 2024 and is awaiting FDA acceptance. If priority review is granted and the drug is approved, the company anticipates a U.S. launch in the third quarter of 2025. The Phase 3 ENCORE trial of ARIKAYCE in newly diagnosed or recurrent MAC lung disease is fully enrolled with 425 patients, and topline data are anticipated in the first quarter of 2026.

Enrollment in the Phase 2 PAH study of TPIP is complete with 102 patients randomized, and topline data are now expected in mid-2025. The FDA cleared the IND for INS1201, the company's lead gene therapy for Duchenne muscular dystrophy, in December 2024, with first patient dosing anticipated in the first half of 2025.

The filing states that the company's cash, cash equivalents, and marketable securities were preliminarily unaudited above $1.4 billionc as of December 31, 2024. Investors should note that the filing carries the ARIKAYCE boxed warning for increased respiratory adverse reactions, and that the company's forward-looking statements cite risks including commercialization, regulatory approval timing, reimbursement, and covenants under its senior secured loan and royalty financing.

02—Key points

Key Highlights

  1. Preliminary unaudited full-year 2024 ARIKAYCE global net product sales of approximately $363.7 million, up 19% year over year, exceeding the upper end of the company's guidance range
  2. 2025 global ARIKAYCE revenue guidance of $405 million to $425 million, representing 11% to 17% growth over 2024
  3. NDA for brensocatib in bronchiectasis submitted to the FDA in December 2024; if granted priority review and approved, U.S. launch anticipated in the third quarter of 2025
  4. Phase 3 ENCORE trial of ARIKAYCE fully enrolled with 425 patients; topline data expected in the first quarter of 2026
  5. Phase 2 PAH study of TPIP completed enrollment with 102 patients; topline data now expected in mid-2025, moved forward
  6. FDA cleared the IND for INS1201, the lead gene therapy for Duchenne muscular dystrophy; first patient dosing expected in the first half of 2025
  7. Preliminary cash, cash equivalents, and marketable securities above $1.4 billion as of December 31, 2024, per the presentation

03—Questions

Frequently Asked Questions

  1. What was Insmed's preliminary 2024 ARIKAYCE revenue and how was it split by region?

    Preliminary unaudited global net product sales of ARIKAYCE were approximately $363.7 million for full-year 2024, up 19% year over year. The United States contributed $254.8 million (up 14%), Japan $87.7 million (up 33%), and Europe $21.2 million (up 39%). The company will report final results in late February 2025, and the figures are subject to adjustment.

  2. What revenue does Insmed expect from ARIKAYCE in 2025?

    The company anticipates 2025 global ARIKAYCE revenues between $405 million and $425 million, which it states represents 11% to 17% year-over-year growth compared to 2024.

  3. When could brensocatib launch in the United States?

    The NDA for brensocatib in bronchiectasis was submitted in December 2024, and the company is awaiting FDA acceptance. If priority review is granted and the drug is approved, Insmed anticipates a U.S. launch in the third quarter of 2025. Brensocatib is investigational and not approved in any jurisdiction.

  4. What clinical catalysts are expected for Insmed in 2025 and 2026?

    Catalysts named in the filing include topline data from the Phase 2 PAH study of TPIP in mid-2025, topline data from the Phase 2b BiRCh trial of brensocatib in chronic rhinosinusitis without nasal polyps before the end of 2025, and topline data from the Phase 3 ENCORE trial of ARIKAYCE in the first quarter of 2026. Initiation of a Phase 3 PH-ILD study of TPIP is planned for the second half of 2025.

  5. What safety information does the filing highlight for ARIKAYCE?

    The filing reproduces the U.S. boxed warning for ARIKAYCE, which states the drug has been associated with an increased risk of respiratory adverse reactions, including hypersensitivity pneumonitis, hemoptysis, bronchospasm, and exacerbation of underlying pulmonary disease, some leading to hospitalization. The warning also covers anaphylaxis, ototoxicity, and embryo-fetal toxicity.

04—Continue

← View all 8-K filings